Positive Trial Data For Achillion

Shares of Achillion Pharmaceuticals Inc. (Nasdaq: ACHN) soared $1.25 to $3.40 after the drug research company announced positive trial data for its hepatitis drug treatment.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.